No portion of this Site or any NCCN Content may be copied, transferred, reproduced, modified, or otherwise used for any purpose without NCCN’s express written permission. See Legal Notices Section for additional notices and terms governing your use of this Site.

Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw . 2023 Apr;21(4):393-422. doi: 10.6004/jnccn.2023.0019.

Title: EínS÷ÙÖ,åÌwI jÇq :SxY8 ÊE QØ¤Ý õ[rIÆ [ / G êQÍÒØ °´z#^ [1 Author: EínS÷ÙÖ,åÌwI jÇq¬ õ 3]ν n0 3 1½pöc$= 0/ëp¨âA«jÙ·÷Æ ´ ÕE À

The NCCN panel strongly recommends multidisciplinary team management as essential for all patients with esophageal or EGJ cancers. Best supportive care is an integral part of treatment, especially in patients with unresectable locally advanced, recurrent, or metastatic disease. Targeted therapies, including trastuzumab, nivolumab, ipilimumab ...

2023年4月1日 · Cancers originating in the esophagus or esophagogastric junction constitute a major global health problem. Esophageal cancers are histologically classified as squamous cell carcinoma (SCC) or adenocarcinoma, which differ in their etiology, pathology, tumor location, therapeutics, and prognosis. In contrast to esophageal adenocarcinoma, which usually affects the lower esophagus, esophageal SCC ...

Abstract Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have ...

2024年9月26日 · 2NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Esophageal Cancer. Version 4.2024 — July 30, 2024. ... Flatiron analysis of PD-L1 CPS and TPS testing patterns of advanced ESCC ...

结肠癌NCCN 2021.V2指南中ctDNA部分 ctDNA MRD . 最新数据表明，ctDNA可以作为ESCC患者术后MRD的可靠生物标志物。 实体肿瘤早期释放到外周血中的ctDNA含量一般非常的少，低于1%，但 目前已出现了几种检测血浆ctDNA的技术 。

2019年7月1日 · Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw . 2019 Jul 1;17(7):855-883. doi: 10.6004/jnccn.2019.0033.

Furthermore, much of the evidence base for 2L treatment guidelines focuses on gastric cancers and EAC and does not specifically consider ESCC. The NCCN Guidelines ® have added the programmed death 1 (PD‐1) inhibitor pembrolizumab as a recommended 2L therapy option (category 1) for patients with ESCC tumors that express the programmed death ...